Research ExplorerPublicationsImproved outcomes over time and higher mortality in CMV sero...

Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry

Standard

Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry. / Ljungman, Per; Tridello, Gloria; Piñana, Jose Luis; Ciceri, Fabio; Sengeloev, Henrik; Kulagin, Alexander; Mielke, Stephan; Yegin, Zeynep Arzu; Collin, Matthew; Einardottir, Sigrun; Lepretre, Sophie Ducastelle; Maertens, Johan; Campos, Antonio; Metafuni, Elisabetta; Pichler, Herbert; Folber, Frantisek; Solano, Carlos; Nicholson, Emma; Yüksel, Meltem Kurt; Carlson, Kristina; Aguado, Beatriz; Besley, Caroline; Byrne, Jenny; Heras, Immaculada; Dignan, Fiona; Kröger, Nicolaus; Robin, Christine; Khan, Anjum; Lenhoff, Stig; Grassi, Anna; Dobsinska, Veronika; Miranda, Nuno; Jimenez, Maria-Jose; Yonal-Hindilerden, Ipek; Wilson, Keith; Averbuch, Dina; Cesaro, Simone; Xhaard, Alienor; Knelange, Nina; Styczynski, Jan; Mikulska, Malgorzata; de la Camara, Rafael.

In: FRONT IMMUNOL, Vol. 14, 2023, p. 1125824.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Ljungman, P, Tridello, G, Piñana, JL, Ciceri, F, Sengeloev, H, Kulagin, A, Mielke, S, Yegin, ZA, Collin, M, Einardottir, S, Lepretre, SD, Maertens, J, Campos, A, Metafuni, E, Pichler, H, Folber, F, Solano, C, Nicholson, E, Yüksel, MK, Carlson, K, Aguado, B, Besley, C, Byrne, J, Heras, I, Dignan, F, Kröger, N, Robin, C, Khan, A, Lenhoff, S, Grassi, A, Dobsinska, V, Miranda, N, Jimenez, M-J, Yonal-Hindilerden, I, Wilson, K, Averbuch, D, Cesaro, S, Xhaard, A, Knelange, N, Styczynski, J, Mikulska, M & de la Camara, R 2023, 'Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry', FRONT IMMUNOL, vol. 14, pp. 1125824. https://doi.org/10.3389/fimmu.2023.1125824

APA

Ljungman, P., Tridello, G., Piñana, J. L., Ciceri, F., Sengeloev, H., Kulagin, A., Mielke, S., Yegin, Z. A., Collin, M., Einardottir, S., Lepretre, S. D., Maertens, J., Campos, A., Metafuni, E., Pichler, H., Folber, F., Solano, C., Nicholson, E., Yüksel, M. K., ... de la Camara, R. (2023). Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry. FRONT IMMUNOL, 14, 1125824. https://doi.org/10.3389/fimmu.2023.1125824

Vancouver

Ljungman P, Tridello G, Piñana JL, Ciceri F, Sengeloev H, Kulagin A et al. Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry. FRONT IMMUNOL. 2023;14:1125824. https://doi.org/10.3389/fimmu.2023.1125824

Bibtex

@article{fd3a149fbe36454bbe7347b2b91e4b5c,
title = "Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry",
abstract = "INTRODUCTION: COVID-19 has been associated with high morbidity and mortality in allogeneic hematopoietic stem cell transplant (allo-HCT) recipients.METHODS: This study reports on 986 patients reported to the EBMT registry during the first 29 months of the pandemic.RESULTS: The median age was 50.3 years (min - max; 1.0 - 80.7). The median time from most recent HCT to diagnosis of COVID-19 was 20 months (min - max; 0.0 - 383.9). The median time was 19.3 (0.0 - 287.6) months during 2020, 21.2 (0.1 - 324.5) months during 2021, and 19.7 (0.1 - 383.9) months during 2022 (p = NS). 145/986 (14.7%) patients died; 124 (12.6%) due to COVID-19 and 21 of other causes. Only 2/204 (1%) fully vaccinated patients died from COVID-19. There was a successive improvement in overall survival over time. In multivariate analysis, increasing age (p<.0001), worse performance status (p<.0001), contracting COVID-19 within the first 30 days (p<.0001) or 30 - 100 days after HCT (p=.003), ongoing immunosuppression (p=.004), pre-existing lung disease (p=.003), and recipient CMV seropositivity (p=.004) had negative impact on overall survival while patients contracting COVID-19 in 2020 (p<.0001) or 2021 (p=.027) had worse overall survival than patients with COVID-19 diagnosed in 2022.DISCUSSION: Although the outcome of COVID-19 has improved, patients having risk factors were still at risk for severe COVID-19 including death.",
keywords = "Humans, Middle Aged, Bone Marrow, Transplantation, Homologous, COVID-19/complications, Hematopoietic Stem Cell Transplantation/adverse effects, Communicable Diseases/complications, Cytomegalovirus Infections/complications, Registries",
author = "Per Ljungman and Gloria Tridello and Pi{\~n}ana, {Jose Luis} and Fabio Ciceri and Henrik Sengeloev and Alexander Kulagin and Stephan Mielke and Yegin, {Zeynep Arzu} and Matthew Collin and Sigrun Einardottir and Lepretre, {Sophie Ducastelle} and Johan Maertens and Antonio Campos and Elisabetta Metafuni and Herbert Pichler and Frantisek Folber and Carlos Solano and Emma Nicholson and Y{\"u}ksel, {Meltem Kurt} and Kristina Carlson and Beatriz Aguado and Caroline Besley and Jenny Byrne and Immaculada Heras and Fiona Dignan and Nicolaus Kr{\"o}ger and Christine Robin and Anjum Khan and Stig Lenhoff and Anna Grassi and Veronika Dobsinska and Nuno Miranda and Maria-Jose Jimenez and Ipek Yonal-Hindilerden and Keith Wilson and Dina Averbuch and Simone Cesaro and Alienor Xhaard and Nina Knelange and Jan Styczynski and Malgorzata Mikulska and {de la Camara}, Rafael",
note = "Copyright {\textcopyright} 2023 Ljungman, Tridello, Pi{\~n}ana, Ciceri, Sengeloev, Kulagin, Mielke, Yegin, Collin, Einardottir, Lepretre, Maertens, Campos, Metafuni, Pichler, Folber, Solano, Nicholson, Y{\"u}ksel, Carlson, Aguado, Besley, Byrne, Heras, Dignan, Kr{\"o}ger, Robin, Khan, Lenhoff, Grassi, Dobsinska, Miranda, Jimenez, Yonal-Hindilerden, Wilson, Averbuch, Cesaro, Xhaard, Knelange, Styczynski, Mikulska and de la Camara.",
year = "2023",
doi = "10.3389/fimmu.2023.1125824",
language = "English",
volume = "14",
pages = "1125824",
journal = "FRONT IMMUNOL",
issn = "1664-3224",
publisher = "Lausanne : Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry

AU - Ljungman, Per

AU - Tridello, Gloria

AU - Piñana, Jose Luis

AU - Ciceri, Fabio

AU - Sengeloev, Henrik

AU - Kulagin, Alexander

AU - Mielke, Stephan

AU - Yegin, Zeynep Arzu

AU - Collin, Matthew

AU - Einardottir, Sigrun

AU - Lepretre, Sophie Ducastelle

AU - Maertens, Johan

AU - Campos, Antonio

AU - Metafuni, Elisabetta

AU - Pichler, Herbert

AU - Folber, Frantisek

AU - Solano, Carlos

AU - Nicholson, Emma

AU - Yüksel, Meltem Kurt

AU - Carlson, Kristina

AU - Aguado, Beatriz

AU - Besley, Caroline

AU - Byrne, Jenny

AU - Heras, Immaculada

AU - Dignan, Fiona

AU - Kröger, Nicolaus

AU - Robin, Christine

AU - Khan, Anjum

AU - Lenhoff, Stig

AU - Grassi, Anna

AU - Dobsinska, Veronika

AU - Miranda, Nuno

AU - Jimenez, Maria-Jose

AU - Yonal-Hindilerden, Ipek

AU - Wilson, Keith

AU - Averbuch, Dina

AU - Cesaro, Simone

AU - Xhaard, Alienor

AU - Knelange, Nina

AU - Styczynski, Jan

AU - Mikulska, Malgorzata

AU - de la Camara, Rafael

N1 - Copyright © 2023 Ljungman, Tridello, Piñana, Ciceri, Sengeloev, Kulagin, Mielke, Yegin, Collin, Einardottir, Lepretre, Maertens, Campos, Metafuni, Pichler, Folber, Solano, Nicholson, Yüksel, Carlson, Aguado, Besley, Byrne, Heras, Dignan, Kröger, Robin, Khan, Lenhoff, Grassi, Dobsinska, Miranda, Jimenez, Yonal-Hindilerden, Wilson, Averbuch, Cesaro, Xhaard, Knelange, Styczynski, Mikulska and de la Camara.

PY - 2023

Y1 - 2023

N2 - INTRODUCTION: COVID-19 has been associated with high morbidity and mortality in allogeneic hematopoietic stem cell transplant (allo-HCT) recipients.METHODS: This study reports on 986 patients reported to the EBMT registry during the first 29 months of the pandemic.RESULTS: The median age was 50.3 years (min - max; 1.0 - 80.7). The median time from most recent HCT to diagnosis of COVID-19 was 20 months (min - max; 0.0 - 383.9). The median time was 19.3 (0.0 - 287.6) months during 2020, 21.2 (0.1 - 324.5) months during 2021, and 19.7 (0.1 - 383.9) months during 2022 (p = NS). 145/986 (14.7%) patients died; 124 (12.6%) due to COVID-19 and 21 of other causes. Only 2/204 (1%) fully vaccinated patients died from COVID-19. There was a successive improvement in overall survival over time. In multivariate analysis, increasing age (p<.0001), worse performance status (p<.0001), contracting COVID-19 within the first 30 days (p<.0001) or 30 - 100 days after HCT (p=.003), ongoing immunosuppression (p=.004), pre-existing lung disease (p=.003), and recipient CMV seropositivity (p=.004) had negative impact on overall survival while patients contracting COVID-19 in 2020 (p<.0001) or 2021 (p=.027) had worse overall survival than patients with COVID-19 diagnosed in 2022.DISCUSSION: Although the outcome of COVID-19 has improved, patients having risk factors were still at risk for severe COVID-19 including death.

AB - INTRODUCTION: COVID-19 has been associated with high morbidity and mortality in allogeneic hematopoietic stem cell transplant (allo-HCT) recipients.METHODS: This study reports on 986 patients reported to the EBMT registry during the first 29 months of the pandemic.RESULTS: The median age was 50.3 years (min - max; 1.0 - 80.7). The median time from most recent HCT to diagnosis of COVID-19 was 20 months (min - max; 0.0 - 383.9). The median time was 19.3 (0.0 - 287.6) months during 2020, 21.2 (0.1 - 324.5) months during 2021, and 19.7 (0.1 - 383.9) months during 2022 (p = NS). 145/986 (14.7%) patients died; 124 (12.6%) due to COVID-19 and 21 of other causes. Only 2/204 (1%) fully vaccinated patients died from COVID-19. There was a successive improvement in overall survival over time. In multivariate analysis, increasing age (p<.0001), worse performance status (p<.0001), contracting COVID-19 within the first 30 days (p<.0001) or 30 - 100 days after HCT (p=.003), ongoing immunosuppression (p=.004), pre-existing lung disease (p=.003), and recipient CMV seropositivity (p=.004) had negative impact on overall survival while patients contracting COVID-19 in 2020 (p<.0001) or 2021 (p=.027) had worse overall survival than patients with COVID-19 diagnosed in 2022.DISCUSSION: Although the outcome of COVID-19 has improved, patients having risk factors were still at risk for severe COVID-19 including death.

KW - Humans

KW - Middle Aged

KW - Bone Marrow

KW - Transplantation, Homologous

KW - COVID-19/complications

KW - Hematopoietic Stem Cell Transplantation/adverse effects

KW - Communicable Diseases/complications

KW - Cytomegalovirus Infections/complications

KW - Registries

U2 - 10.3389/fimmu.2023.1125824

DO - 10.3389/fimmu.2023.1125824

M3 - SCORING: Journal article

C2 - 36960069

VL - 14

SP - 1125824

JO - FRONT IMMUNOL

JF - FRONT IMMUNOL

SN - 1664-3224

ER -